Improved synthesis of gefitinib and erlotinib hydrochloride- anticancer agents

Synthetic Communications

Volumn 37, Issue 19, 2007, Pages 3409-3415

  Chandregowda, Venkateshappa ^a   Rao, Gudapati Venkateswara ^a   Reddy, Goukanapalli Chandrasekara ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Erlotinib; Gefitinib; Methylthio quinazolines; Nonsmall cell lung cancer; Tyrosine kinase inhibitors (TKIs)

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PANCREAS CANCER; POTENTIOMETRIC TITRATION; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 35148865335     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397910701483761     Document Type: Article

References (10)

1. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21, 2787-2799.
2. Ciardiello, F.; De Vita, F.; Orditura, M.; De Placido, S.; Tortora, G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Exp. Opin. Emerg. Drugs 2003, 8, 501-514.
3. Vansteenkiste, J. F. Gefitinib (iressa): A novel treatment for non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2004, 4, 5-17.
4. Bonomi, P. Erlotinib: A new therapeutic approach for non-small-cell lung cancer. Expert Opin. Invest. Drugs 2003, 12, 1395-1401.
5. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jaenne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
6. Blackhall, F.; Ranson, M.; Thatcher, N. Where next for gefitinib in patients with lung cancer? Lancet Oncology 2006, 7, 499-507.
7. Marshall, J. Implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006, 107, 1207-1218.
8. Johnson, D. H. Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2006, 12, 4451s-4457s.
9. Chandregowda, V.; Rao, G. V.; Reddy, G. C. One-pot conversion of 2-nitrobenzonitriles to quinazoline-4(3H)-ones and synthesis of gefitinib and erlotinib hydrochloride. Heterocycles 2007, 71, 39-48, and references cited therein.
10. Knesl, P.; Röseling, D.; Jordis, U. Improved synthesis of substituted 6,7-dihydroxy-4-quinazoline amines: Tandutinib, erlotinib, and gefitinib. Molecules 2006, 11, 286-287and references cited therein.